Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells

Nanomedicine

Volumn 7, Issue 10, 2012, Pages 1591-1610

  Cruz, Luis J ^a,b   Rueda, Felix ^b   Tacken, Paul ^a   Albericio, Fernando ^b,c   Torensma, Ruurd ^a   Figdor, Carl G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

carrier conjugates; cross reactivity; delivery vehicle; HIV 1; immunogenicity; nanoparticle; specific ligands; synthetic peptide vaccines; targeting; V3 loop

Indexed keywords

ANTIRETROVIRUS AGENT; CARRIER PROTEIN; CD209 ANTIGEN; DENDRITIC CELL VACCINE; DNA VACCINE; DRUG CARRIER; FC RECEPTOR; GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INACTIVATED VIRUS VACCINE; LECTIN RECEPTOR; LIPOSOME; MACROGOL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MULTIPLE ANTIGEN PEPTIDE VACCINE; NANOPARTICLE; NEF PROTEIN; PEPTIDE VACCINE; POL PROTEIN; POLYMER; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIROSOME; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIGEN PRESENTATION; CELLULAR IMMUNITY; COMBINATORIAL LIBRARY; CONJUGATION; CROSS REACTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG TARGETING; EXOSOME; GENE TRANSFER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; MACROMOLECULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; VACCINATION; VIRION; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS LIKE AGENT;

AIDS VACCINES; CROSS REACTIONS; DENDRITIC CELLS; HIV ANTIGENS; HIV-1; HUMANS;

EID: 84869466586     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.131     Document Type: Review

References (171)

1. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV1 infection. Annu. Rev. Immunol. 21, 265-304 (2003).
2. Domingo P, Torres-Torronteras J, Pomar V et al. Uridine metabolism in HIV1-infected patients: effect of infection, of antiretroviral therapy and of HIV1/ART-associated lipodystrophy syndrome. PLoS One 5(11), e13896 (2010).
3. Berzofsky JA, Ahlers JD, Janik J et al. Progress on new vaccine strategies against chronic viral infections. J. Clin. Invest. 114, 450-462 (2004).
4. Egan MA. Current prospects for the development of a therapeutic vaccine for the treatment of HIV type 1 infection. AIDS Res. Hum. Retrovir. 20, 794-806 (2004).
5. Palmisano L, Vella S. A brief history of antiretroviral therapy of HIV infection: Success and challenges. Ann. Ist Super Sanita. (1), 44-48 (2011).
6. Lévy Y, Gahéry-Ségard H, Durier C et al. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV1 infected patients. AIDS 19, 279-286 (2005).
7. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic- cell vaccine for chronic HIV1 infection. Nat. Med. 10, 1359-1365
8. Leitner T. Genetic subtypes of HIV1. In: Human Retrovirus and AIDS: A Compilation of Nucleic Acids and Amino Acid Sequences
9. Myers G, Korber BT, Foley BT, Jeang KT, Mellors J, Wain-Hobson S (Eds). Los Alamos National Laboratory, NM, USA, III28 (1996).
10. Fanales-Belasio E, Moretti S, Nappi F et al. Native HIV1 Tat protein targets monocytederived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J. Immunol. 168(1), 197-206 (2002).
11. Izmailova E, Bertley FM, Huang Q et al. HIV1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat. Med. 9(2), 191-197 (2003).
12. García F, Routy JP Challenges in dendritic cells-based therapeutic vaccination in HIV1 infection workshop in dendritic cell-based vaccine clinical trials in HIV1. Vaccine 29(38), 6454-6463 (2011).
13. Patham B, Simmons GL, Subramanya S. Advances in dendritic cell-based vaccines for HIV. Curr. Med. Chem. 18(26), 3987-3994 (2011).
14. Goldstein G, Chicca II JJ. A universal anti-HIV1 Tat epitope vaccine that is fully synthetic and self-adjuvanting. Vaccine 28, 1008-1014 (2010).
15. Wu L, Yang ZY, Xu L et al. Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope. Vaccine 24, 4995-5002 (2006).
16. Lu L, Zhu Y, Diao J, Wang Z, Chen YH. V3 CTL epitope density in a single recombinant molecule antigen differentially affects the number and activity of primary and memory CD8+ T cells. Vaccine 26, 845-852 (2008).
17. Rubinstein A, Goldstein H, Pettoello-Mantovani M et al Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers. AIDS 9, 243-251 (1995).
18. Yamanaka T, Fujimura Y, Ishimoto S et al. Correlation of titer of antibody to principal neutralizing domain of HIVMN strain with disease progression in Japanese hemophiliacs seropositive for HIV type 1. AIDS Res. Hum. Retroviruses 4, 317-326 (1997).
19. Berzofsky JA. Development of artificial vaccines against HIV using defined epitopes. FASEB J. 5, 2412-2418 (1991).
20. Pantophlet R, Wrin T, Cavacini LA, Robinson JE, Burton DR. Neutralizing activity of antibodies to the V3 loop region of HIV1 gp120 relative to their epitope fine specificity. Virology 381(2), 251-260 (2008).
21. de Souza MS, Ratto-Kim S, Chuenarom W et al. Thai Phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV1 envelope. J. Immunol. (10), 5166-5176 (2012).
22. Montefiori DC, Karnasuta C, Huang Y et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV1 Vaccine Efficacy Trials. J. Infect. Dis.(3), 431-441 (2012).
23. Haynes BF, Moody MA, Liao HX, Verkoczy L, Tomaras GD. B cell responses to HIV1 infection and vaccination: pathways to preventing infection. Trends Mol. Med. 17(2), 108-116 (2011).
24. Spearman P, Kalams S, Elizaga M et al. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a Phase I trial. Vaccine 27(2), 243-249 (2009).
25. Bråve A, Hallengärd D, Malm M et al. Combining DNA technologies and different modes of immunization for induction of humoral and cellular anti-HIV1 immune responses. Vaccine 27(2), 184-186 (2009).
26. Barouch DH, O'Brien KL, Simmons NL et al. Mosaic HIV1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med.(3), 319-323 (2010).
27. Dittmer U, Werner T, Kraft AR. Coimmunization of mice with a retroviral DNA vaccine and GITRL-encoding plasmid augments vaccine-induced protection against retrovirus infection. Viral Immunol. 21(4), 459-467 (2008).
28. Schilling R, Heil A, Langner K et al. A multivalent HIV-vaccine: development of a plasmid DNA for the expression of HIV envelope glycoproteins with hypervariable V3-loop domains. Vaccine 24, 4648-4650 (2006).
29. Lu S. Immunogenicity of DNA vaccines in humans. Human Vaccines 4(6), 449-452
30. Romain G, van Gulck E, Epaulard O et al. CD34-derived dendritic cells transfected ex vivo with HIV-Gag mRNA induce polyfunctional T-cell responses in nonhuman primates. Eur. J. Immunol. doi:10.1002/eji.201242478 (2012) (Epub ahead of print).
31. Allard SD, De Keersmaecker B, de Goede AL et al. A Phase I/IIa immunotherapy trial of HIV1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. Clin. Immunol. (3), 252-268 (2012).
32. Van Gulck E, Vlieghe E, Vekemans M et al. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV1-infected patients. AIDS 26(4), F1-12 (2012).
33. Toledo H, Baly A, Castro O et al. A Phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV1 infected human volunteers. Vaccine 19(30), 4328-4336 (2001).
34. Rosenberg ES, Graham BS, Chan ES et al. Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV1 infection. PLoS One 5(5), e10555 (2010).
35. Jin X, Newman MJ, De-Rosa S et al. A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4+ T cells in a Phase I clinical trial in HIVuninfected adults. Vaccine 27(50), 7080- (2009).
36. Cruz LJ, Iglesias E, Aguilar JC et al. A comparative study of different presentation strategies for an HIV peptide immunogen. Bioconjug. Chem. 15, 112-120 (2004).
37. Jones T. Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection. Curr. Opin. Investig. Drugs 11(8), 964-970 (2010).
38. Iglesias E, Aguilar JC, Cruz LJ, Reyes O. Broader cross-reactivity after conjugation of V3 based multiple antigen peptides to HBsAg. Mol. Immunol. 42, 99-104 (2005).
39. Cruz LJ, Iglesias E, Garay HE, Besada V, Reyes O. Linear polymerization of a synthetic peptide of the V3 region from HIV1 JY1 isolate using acetamidomethyl-protected thiol groups of cysteine residues. Biotecnol. Aplic. 35-38 (2000).
40. Cruz LJ, Padron R, Gonzalez LJ et al. Peptide synthesis containing a B-cell and a T-cell epitope on dextran beads and evaluation of humoral response against bead-peptide construct. Lett. Pept. Sci. 7, 229-237 (2001).
41. Cruz LJ, Iglesias E, Aguilar JC et al. Study of different coupling agents in the conjugation of a V3-based synthetic MAP to carrier proteins. J. Pept. Sci. 7, 511-518 (2001).
42. Cruz LJ, Iglesias E, Aguilar JC et al. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from Human Immunodeficiency Virus type 1. Bioconjug. Chem. 15, 1110-1117 (2004).
43. Cruz LJ, Cabrales A, Iglesias E, Aguilar JC, González LJ, Reyes O V3-peptide and multiple antigen peptides conjugated to distinct carrier proteins. Int. Immunopharmacol. 9(12), 1452-1459 (2009).
44. Gras-Masse H, Boutillon C, Dieses E, Deprez B, Tartar A. Confronting the degeneracy of convergent combinatorial immunogens, or 'mixotopes', with the specificity of recognition of the target sequences. Vaccine 15, 1568 (1997).
45. Thammavongsa V, Schaefer M, Filzen T et al. Assembly and intracellular trafficking of HLA-B. 3501 and HLA-B. 3503.Immunogenetics 61(11-12), 703-716 (2009).
46. Smith AD, Geisler SC, Chen AA et al. Human rhinovirus type 14: human immunodeficiency virus type 1 (HIV1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV1. J. Virol. 72, 651-659 (1998).
47. Resnick DA, Smith AD, Gesiler SC et al. Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV1) V3 loop seroprevalence library induce neutralizing responses against HIV1. J. Virol. 4, 2406-2411 (1995).
48. Hart MK, Palker TJ, Haynes BF. Design of experimental synthetic peptide immunogens for prevention of HIV1 and HTLV-I retroviral infections. Pharm. Biotechnol. 6, 821-845 (1995).
49. Pitisuttithum P, Gilbert P, Gurwith M et al. Randomized, double-blind, placebocontrolled efficacy trial of a bivalent recombinant glycoprotein 120 HIV1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661-1671 (2006).
50. Gilbert PB, Peterson ML, Follmann D et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV1 infection in a Phase 3 HIV1 preventive vaccine trial. J. Infect. Dis. 666-677 (2005).
51. Salmon-Céron D, Durier C, Desaint C et al. Immunogenicity and safety of an HIV1 lipopeptide vaccine in healthy adults: A Phase 2 placebo-controlled ANRS trial. AIDS 24(14), 2211-2223 (2010).
52. Zhou Y, Bosch ML, Salgaller ML. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J. Immunother. 25, 289-303
53. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188, 2199-2204 (1998).
54. Yoshida A, Tanaka R, Murakami T et al. Induction of protective immune responses against R5 human immunodeficiency virus type 1 (HIV1) infection in hu-PBL-SCID mice by intrasplenic immunization with HIV1-pulsed dendritic cells: possible involvement of a novel factor of human CD4+ T-cell origin. J. Virol. 77(16), 8719-8728 (2003).
55. Lapenta C, Santini SM, Logozzi M et al. Potent immune response against HIV1 and protection from virus challenge in hu-PBLSCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J. Exp. Med. 198(2), 361-367 (2003).
56. Lu W, Wu X, Lu Y, Guo W, Andrieu JM. Therapeutic dendritic-cell vaccine for simian AIDS. Nat. Med. 9(1), 27-32 (2003).
57. Andrieu JM, Lu W. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results. J. Intern. Med. 1(2), 123-131 (2007).
58. Whiteside TL, Piazza P, Reiter A et al. Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. Clin. Vaccine Immunol. 16(2), 233-240
59. García F, Climent N, Assoumou L et al. A therapeutic dendritic cell-based vaccine for HIV1 infection. J. Infect. Dis. 203(4), 473-478 (2011).
60. Huang XL, Fan Z, Zheng L et al. Priming of human immunodeficiency virus type 1 (HIV1)-specific CD8+ T cell responses by dendritic cells loaded with HIV1 proteins. J. Infect. Dis. 187, 315-319 (2003).
61. Alexaki A, Wigdahl B. HIV1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination. PLoS Pathogens 4(12), e1000215 (2008).
62. Fantuzzi L, Purificato C, Donato K, Belardelli F, Gessani S. Human immunodeficiency virus type 1 gp120 induces abnormal maturation and functional alterations of dendritic cells: A novel mechanism for AIDS pathogenesis. J. Virol. (18), 9763-9772 (2004).
63. Fanales-Belasio E, Cafaro A, Cara A et al. HIV1 Tatbased vaccines: From basic science to clinical trials. DNA Cell Biol. 21, 599-610 (2002).
64. Gavioli R, Gallerani E, Fortini C et al. HIV1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J. Immunol. 173, 3838-3843
65. Kasper MR, Collins KL. Nef-mediated disruption of HLA-A2 transport to the cell surface in T-cells. J. Virol. 77, 3041-3049 (2003).
66. Yang OO, Nguyen PT, Kalams SA et al. Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J. Virol. 76, 1626-1631 (2002).
67. Stumptner-Cuvelette P, Morchoisne S, Dugast M et al. HIV1 Nef impairs MHC class II antigen presentation and surface expression. Proc. Natl Acad. Sci. USA 98(21), 12144-12149 (2001).
68. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184(2), 465-472 (1996).
69. Mitchell DA, Nair SK. RNA-transfected dendritic cells in cancer immunotherapy. J. Clin. Invest. 106, 1065-1069 (2000).
70. Tillman BW, Hayes TL, DeGruijl TD, Douglas JT, Curiel DT. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res. 60, 5456-5463 (2000).
71. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA transfected dendritic cells. Immunol. Rev. 199, 251-263 (2004).
72. Brown K, Gao W, Alber S et al. Adenovirustransduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T cell immunity in monkeys. J. Immunol. 171, 6875-6882 (2003).
73. Xin KQ, Hoshino Y, Toda Y et al. Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood 102, 223-228 (2003).
74. Kappes JC, Wu X. Safety considerations in vector development. Somat. Cell Mol. Genet. 147-158 (2001).
75. Rudolf MP, Fausch SC, Da Silva DM, Kast WMLLL viruslike particles and induce epitope-specific human T cell responses in vitro. J. Immunol. 5917-5924 (2001).
76. Touze A, Coursaget P. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res. 26(5), 1317-1323 (1998).
77. Chaput N, Taïeb J, André F, Zitvogel L. The potential of exosomes in immunotherapy. Expert Opin. Biol. Ther. 5(6), 737-747, (2005).
78. Li X, Zhang Z, Beiter T, Schluesener HJ. Nanovesicular vaccines: exosomes. Arch. Immunol. Ther. Exp. (Warsz) 53(4), 329-235
79. André F, Chaput N, Schartz NE et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J. Immunol. (4), 2126-2136 (2004).
80. Wingard JB, Anderson B, Weissman D. Induction of HIV-specific T and B cell responses with a replicating and conditionally infectious lentiviral vaccine. Eur. J. Immunol. (5), 1310-1320 (2008).
81. Coren LV, Shatzer T, Ott DE immunoaffinity depletion of vesicles from Jurkat T cells demonstrates that exosomes contain CD45: no evidence for a distinct exosome/HIV1 budding pathway. Retrovirology 16, 50-64 (2008).
82. Wiley RD, Gummuluru S. Immature dendritic cell-derived exosomes can mediate HIV1 transinfection. Proc. Natl Acad. Sci. USA 103(3), 738-743 (2006).
83. Nanjundappa RH, Wang R, Xie Y et al. GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4+T-independent CTL responses. Vaccine 29(19), 3538-3547 (2011).
84. Li M, Aliotta JM, Asara JM et al. Quantitative proteomic analysis of exosomes from HIV1-infected lymphocytic cells. Proteomics 12(13), 2203-2211 (2012).
85. Lenassi M, Cagney G, Liao M et al. HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Traffic. 11(1), 110-122 (2010).
86. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: From ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7(10), 790-802 (2007).
87. Tang J, Yin R, Tian Y et al. A novel selfassembled nanoparticle vaccine with HIV1 Tat(49-57)/HPV16 E7(49-57) fusion peptide and GM-CSF DNA elicits potent and prolonged CD8+ T cell-dependent anti-tumor immunity in mice. Vaccine 30(6), 1071-1082 (2011).
88. Jacobs JFM, Pereira CF, Tacken PJ et al. Ex vivo-generated dendritic cells for clinical trials versus in vivo targeting to dendritic cells: Critical issues. In: The Biology of Dendritic Cells and HIV Infection. Gessani S, Belardelli F (Eds). Springer Science + Business Media, Rome, Italy (2007).
89. Tacken PJ, Torensma R, Figdor CG. Targeting antigens to dendritic cells in vivo. Immunobiology 211(6-8), 599-608 (2006).
90. Moron G, Dadaglio G, Leclerc C. New tools for antigen delivery to the MHC class I pathway. Trends Immunol. 25, 92-97 (2004).
91. Jeannin P, Renno T, Goetsch L et al. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat. Immunol. 1(6), 502-509 (2000).
92. Kawai T, Akira1 S. The role of patternrecognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol. (5), 373-384 (2010).
93. Liu G, Zhao Y. Toll-like receptors and immune regulation: their direct and indirect modulation on regulatory CD4+ CD25+ T cells. Immunology 122, 149-156 (2007).
94. Spaner DE, Masellis A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia 21, 53-60
95. Equils O, Schito ML, Karahashi H et al. Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV1 transgenic mouse spleen cells: Implications of simultaneous activation of TLRs on HIV replication. J. Immunol. 170, 5159-5164 (2003).
96. Breckpot K, Escors D, Arce F et al. HIV1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J. Virol. 84(11), 5627-5636 (2010).
97. Apostolopoulos V, Pietersz GA, Gordon S, Martinez-Pomares L, McKenzie IF. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur. J. Immunol. 30, 1714-1723 (2000).
98. Frison N, Taylor ME, Soilleux E et al. Oligolysine-based oligosaccharide clusters: Selective recognition and endocytosis by the mannose receptor and dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)- grabbing nonintegrin. J. Biol. Chem. 278, 23922-23929 (2003).
99. Nigou J, Zelle-Rieser C, Gilleron M, Thurnher M, Puzo G. Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor. J. Immunol. 166, 7477-7485 (2001).
100. He LZ, Crocker A, Lee J et al. Antigenic targeting of the human mannose receptor induces tumor immunity. J. Immunol. (10), 6259-6267 (2007).
101. Guo M, Gong S, Maric S et al. A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. Hum. Immunol. 61, 729-738 (2000).
102. Bozzacco L, Trumpfheller C, Huang Y et al. HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC. Eur. J. Immunol. 40(1), 36-46
103. Tacken PJ, Figdor CG. Targeted antigen delivery and activation of dendritic cells in vivo: Steps towards cost effective vaccines. Semin. Immunol. 23(1), 12-20 (2011).
104. Thériault JR, Mambula SS, Sawamura T, Stevenson MA, Calderwood SK epithelial cells. FEBS Lett. 579(9), 1951-1960 (2005).
105. Delneste Y, Magistrelli G, Gauchat J et al. Involvement of LOX-1 in dendritic cellmediated antigen crosspresentation. Immunity 17, 353-362 (2002).
106. Idoyaga J, Lubkin A, Fiorese C et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc. Natl Acad. Sci. USA 108(6), 2384-2389 (2011).
107. Martinon F, Dereuddre-Bosquet N, Méderlé-Mangeot I et al. Directing macaque immune responses with an anti-dendritic cell HIV Gag p24 fusion protein vaccine. Retrovirology 6(Suppl. 3), 346 (2009).
108. Soilleux EJ, Morris LS, Leslie G et al. Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J. Leukoc. Biol. 71, 445-457 (2002).
109. Gieseler RK, Marquitan G, Hahn MJ et al. DC-SIGN-specific liposomal targeting and selective intracellular compound delivery to human myeloid dendritic cells: Implications for HIV disease. Scand. J. Immunol. 59, 415-424 (2004).
110. Korokhov N, de Gruijl TD, Aldrich WA et al. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. Cancer Biol. Ther. 4(3), 289-294 (2005).
111. Tacken PJ, de Vries IJ, Gijzen K et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 106(4), 1278-1285 (2005).
112. Moris A, Nobile C, Buseyne F, Porrot F, Abastado J-P, Schwartz O antigen presentation. Blood 103, 2648-2654
113. Poulin LF, Salio M, Griessinger E et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J. Exp. Med. 207(6), 1261-1271 (2010).
114. Joffre OP, Sancho D, Zelenay S, Keller AM, Reis e Sousa C. Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A. Eur. J. Immunol. 40(5), 1255-1265 (2010).
115. Bonifaz LC, Bonnyay DP, Charalambous A et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199, 815-824 (2004).
116. Hudson PJ, Souriau C. Engineered antibodies. Nat. Med. 9, 129-134 (2003).
117. Steinman RM, Bonifaz L, Fujii S et al. The innate functions of dendritic cells in peripheral lymphoid tissues. Adv. Exp. Med. Biol. 560, 83-97 (2005).
118. Grousson J, Peguet-Navarro J. Functional relevance of CD40 expression in human epidermis. Cell Biol. Toxicol. 14, 345-350 (1998).
119. Loof N, Montes M, Flamar A et al. HIV-specific responses induced by anti-CD40 targeting antibodies. Retrovirology 6(Suppl. 3), O46 (2009).
120. Flamar A, Zurawski S, Cobb A et al. Targeting HIV peptides to human dendritic cells via CD40 elicits expansion of multiepitope polyfunctional CD4+ and CD8+ T cells in HIV patients. Retrovirology 6(Suppl. 3), P286 (2009).
121. Serre K, Giraudo L, Leserman L, Machy P. Liposomes targeted to Fc receptors for antigen presentation by dendritic cells in vitro and in vivo. Methods Enzymol. 373, 100-118
122. Ortiz-Stern A, Rosales C. Cross-talk between Fc receptors and integrins. Immunol. Lett. 90, 137-143 (2003).
123. Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J. Immunol. 168, 2240-2246 (2002).
124. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcg receptors on dendritic cells. J. Exp. Med. 195, 1653-1659 (2002).
125. Pasquier B, Launay P, Kanamaru Y et al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 22, 31-42 (2005).
126. Wallace PK, Tsang KY, Goldstein J et al. Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I. J. Immunol. Methods 248, 183-194 (2001).
127. Abdel-Motal UM, Wigglesworth K, Galili U. Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody. Vaccine 27(23), 3072-3082 (2009).
128. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 178, 6596-6603 (2007).
129. Rapaka RR, Goetzman ES, Zheng M et al. Enhanced defense against Pneumocystis carinii mediated by a novel dectin-1 receptor Fc fusion protein. J. Immunol. 178, 3702-3712
130. Zhang MY, Vu BK, Choudhary A et al. Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41and lacks reactivity against self-antigens. J. Virol. 82, 6869-6879 (2008).
131. Duval M, Posner MR, Cavacini LA immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils. J. Virol. 82, 4671-4674 (2008).
132. Perez LG, Costa MR, Todd CA, Haynes BF, Montefiori DC. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: A specific role for antibodies against the membraneproximal external region of gp41. J. Virol. (15), 7397-7410 (2009).
133. French MA, Tanaskovic S, Law MG et al. Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a 'high-affinity' FcgRIIa genotype. AIDS 24(13), 1983-1990 (2010).
134. Rose NF, Marx PA, Luckay A et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106, 539-549 (2001).
135. Hedley SJ, Auf der Maur A, Hohn S et al. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther. (1), 88-94 (2006).
136. Yang L, Yang H, Rideout K et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol. 26(3), 326-334 (2008).
137. Datta SA, Temeselew LG, Crist RM et al On the role of the SP1 domain in HIV1 particle assembly: A molecular switch? J. Virol. 85(9), 4111-4121 (2011).
138. Tanzi E, Esposito S, Bojanin J et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. J. Med. Virol. 78(4), 440-445 (2006).
139. Hattori Y, Kawakami S, Suzuki S, Yamashita F, Hashida M. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Biochem. Biophys. Res. Commun. 317, 992-999 (2004).
140. Joshi MD, Unger WW, van Beelen AJ et al. DC-SIGN mediated antigen-targeting using glycan-modified liposomes: Formulation considerations. Int. J. Pharm. 416(2), 426-432 (2011).
141. Moore A, McGuirk P, Adams S et al. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine 13, 1741-1749 (1995).
142. De Haes W, De Koker S, Pollard C et al. Polyelectrolyte capsules-containing HIV1 p24 and Poly I:C modulate dendritic cells to stimulate HIV1-specific immune responses. Mol. Ther. 18(7), 1408-1416 (2010).
143. Marradi M, Di Gianvincenzo P, Enríquez-Navas PM et al. Gold nanoparticles coated with oligomannosides of HIV1 glycoprotein gp120 mimic the carbohydrate epitope of antibody 2G12. J. Mol. Biol. 410(5), 798-810
144. Schlosser E, Mueller M, Fischer S et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 26(13), 1626-1637 (2008).
145. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6(8), 769-776 (2005).
146. Kasturi SP, Skountzou I, Albrecht RA et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470(7335), 543-547 (2011).
147. Cruz LJ, Tacken PJ, Fokkink R et al. Targeted PLGA nano - but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J. Control Release 144(2), 118-126 (2010).
148. Tacken PJ, Zeelenberg IS, Cruz LJ et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 118(26), 6836-6844 (2011).
149. Gringhuis SI, den Dunnen J, Litjens M, van der Vlist M, Geijtenbeek TB. Carbohydratespecific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV1 and Helicobacter pylori. Nat. Immunol. 10(10), 1081-1088 (2009).
150. Jin HT, Jeong YH, Park HJ, Ha SJ. Mechanism of T cell exhaustion in a chronic environment. BMB Rep. 44(4), 217-231 (2011).
151. Rios CM, Velilla PA, Rugeles MT. Chronically HIV1 infected patients exhibit low frequencies of CD25+ regulatory T cells. Open Virol. J. 6, 49-58 (2012).
152. Moreno-Fernandez ME, Rueda CM, Rusie LK, Chougnet CA. Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism. Blood 117(20), 5372-5380 (2011).
153. Moreno-Fernandez ME, Presicce P, Chougnet CA. Homeostasis and function of regulatory T cells in HIV/SIV infection. J. Virol. doi: 10.1128/JVI.00993-12 (2012) (Epub ahead of print).
154. Angin M, Kwon DS, Streeck H et al. Preserved function of regulatory T cells in chronic HIV1 infection despite decreased numbers in blood and tissue. J. Infect. Dis. (10), 1495-1500 (2012).
155. Presicce P, Orsborn K, King E, Pratt J, Fichtenbaum CJ, Chougnet CA. Frequency of circulating regulatory T cells increases during chronic HIV infection and is largely controlled by highly active antiretroviral therapy. PLoS One 6(12), e28118 (2011).
156. Méndez-Lagares G, del Pozo Balado Mdel M, Genebat González M et al. Severe immune dysregulation affects CD4+CD25hiFoxP3+ regulatory T cells in HIV-infected patients with low-level CD4 T-cell repopulation despite suppressive highly active antiretroviral therapy. J. Infect. Dis. 205(10), 1501-1509
157. Foxall RB, Albuquerque AS, Soares RS et al. Memory and naive-like regulatory CD4+ T cells expand during HIV-2 infection in direct association with CD4+ T-cell depletion irrespectively of viremia. AIDS 25(16), 1961-1970 (2011).
158. Schulze Zur Wiesch J, Thomssen A, Hartjen P et al. Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. J. Virol. 85(3), 1287-1297 (2011).
159. Weiss L, Letimier FA, Carriere M et al. In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients. Proc. Natl Acad. Sci. USA 107(23), 10632-10637 (2010).
160. Elahi S, Dinges WL, Lejarcegui N et al. Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nat. Med.17(8), 989-995 (2011).
161. Presicce P, Shaw JM, Miller CJ, Shacklett BL, Chougnet CA. Myeloid dendritic cells isolated from tissues of SIV-infected Rhesus macaques promote the induction of regulatory T cells. AIDS 26(3), 263-273 (2012).
162. Qin X, Yao J, Yang F, Nie J, Wang Y, Liu PC expands treg cells via Toll-like receptor 2. J. Cell Biochem.112(12), 3515-3524 (2011).
163. Wang X, Zhang Z, Zhang S et al. B7-H1 up-regulation impairs myeloid DC and correlates with disease progression in chronic HIV1 infection. Eur. J. Immunol. 38(11), 3226-3236 (2008).
164. Vollbrecht T, Stirner R, Tufman A et al. Chronic progressive HIV1 infection is associated with elevated levels of myeloid-derived suppressor cells. AIDS 26(12), F31-37 (2012).
165. Zhang M, Zhang H, Zhang T, Ji Y, Jiao Y, Wu H. Longitudinal changes of peripheral blood DC subsets and regulatory T cells in Chinese Chronic HIV1-infected patients during antiretroviral therapy. PLoS One 7(5), e37966 (2012).
166. Xu H, Wang X, Pahar B et al. Increased B7-H1 expression on dendritic cells correlates with programmed death 1 expression on T cells in simian immunodeficiency virus-infected macaques and may contribute to T cell dysfunction and disease progression. J. Immunol. 185(12), 7340-7348 (2010).
167. Li W, Green WR. Immunotherapy of murine retrovirus-induced acquired immunodeficiency by CD4 T regulatory cell depletion and PD-1 blockade. J. Virol. (24), 13342-13353 (2011).
168. De Keersmaecker B, Heirman C, Corthals J et al. The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses. J. Leukoc. Biol. 89(6), 989-999 (2011).
169. Macatangay BJ, Rinaldo CR. Regulatory T cells in HIV immunotherapy. HIV Ther. 4(6), 639-647 (2010).
170. Rinaldo CR. Dendritic cell-based human immunodeficiency virus vaccine. J. Intern. Med. 265, 138-158 (2008).
171. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: From ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7(10), 790-802 (2007).